ReviewFrontiers in pharmacology2026
Low-molecular-weight heparins in atrial fibrillation: clinical scenarios, limitations, and future perspectives.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Atrial fibrillation (AF) is associated with a significantly increased risk of thromboembolic complications, including ischaemic stroke. Despite the dominant role of oral anticoagulants, low-molecular-weight heparins (LMWHs) are still used in selected clinical scenarios. Aim: The aim of this review was to summarise the current clinical role of LMWHs in atrial fibrillation, with particular emphasis on available evidence, practical limitations and selected complex clinical scenarios. Methods: A review based on the analysis of available clinical trials, guidelines, and pharmacological data. Results: Low-molecular-weight heparins are used primarily for bridging therapy and in situations where oral anticoagulation is temporarily contraindicated or not feasible. However, robust evidence supporting the long-term use of LMWHs for stroke prevention in atrial fibrillation remains limited. Conclusion: Low-molecular-weight heparins should not be considered standard chronic therapy for atrial fibrillation. Further studies are needed to better define optimal anticoagulation strategies in patients with atrial fibrillation, particularly in complex clinical settings such as active cancer and thrombocytopenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.